Maurizio Montella

Maurizio Montella

Auto-generated profile, based on publicly available information

Maurizio Montella

Department of Epidemiology, Istituto Nazionale Tumori Pascale, Naples, Italy

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2001 in European Journal Of Cancer Prevention
Verified
Journal Article
Closed access
MMM Montella
M Montella
ACAnna Crispo
Anna Crispo
GDG Dʼaiuto
G Dʼaiuto
MMM De Marco
M De Marco
GBG de Bellis
G de Bellis
PSP Silvesrtra
P Silvesrtra
Randomized trials of mammographic screening have provided strong evidence that early diagnosis and treatment of breast cancer can reduce the specific mortality. Moreover, in a recent systematic review of published studies, delays of 3–6 months between symptom onset and treatment have been clearly found to be associated with lower survival rates for breast cancer patients. The aim of this study was to examine delays registered among breast cancer patients in southern Italy, in order to recognize their determining factors so as to provide women with a better opportunity for survival. The variables examined were age (<50, 50–64, ≥65 years), education (≤5, >5 school years); symptom status at first presentation (symptomatic or asymptomatic); date of first symptom presentation; date of first consultation with a health provider; the type of health provider consulted; tumour size and nodal status according to the pTNM system. Time intervals were categorized into: 3 months for patient and medical delay; 1–3 months, 3–6 months, >6 months for overall delay. Patient delay was associated with age and education: a higher risk was found for women of over 65 years age (odds ratio (OR) 2.1, 95% confidence interval (CI) 1.2–3.5) and with ≤5 years school attendance (OR 3.3, 95% CI 2.0–5.6). Medical delay was seen to be associated with the professional figure: significant differences were found between senologists (oncologists exclusively dedicated to breast cancer operation) and other specialists (OR 3.5, 95% CI 1.5–8.4). Young age and symptomatic presentation were found to be high risk factors. Concerning tumour size in overall delay, in cases where the tumour was >2 cm the OR was 2.4 (95% CI 1.5–3.7). Our study suggests that diagnostic delay can be reduced by providing more efficient training programmes for members of the medical profession and by producing educational training programmes targeted specifically at each age category (i.e. in older women more attention to education in prevention; in younger women correct information about mammography and specialized structures).

1 October 2001 in Liver International
Verified
Journal Article
Closed access
PDF file
MMMaurizio Montella
Maurizio Montella
ACAnna Crispo
Anna Crispo
GBGiovanna De Bellis
Giovanna De Bellis
FIFrancesco Izzo
Francesco Izzo
FFFerdinando Frigeri
Ferdinando Frigeri
OCOreste Cuomo
Oreste Cuomo

1 September 2001 in Leukemia Research
Verified
Journal Article
Closed access
MMMaurizio Montella
Maurizio Montella
ACAnna Crispo
Anna Crispo
FFFerdinando Frigeri
Ferdinando Frigeri
DRDomenico Ronga
Domenico Ronga
VTVincenzo Tridente
Vincenzo Tridente
MTMario Tamburini
Mario Tamburini

29 November 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GAGrazia Arpino
Grazia Arpino
MPMatilde Pensabene
Matilde Pensabene
CCC. Condello
C. Condello
RRR. Ruocco
R. Ruocco
ICI. Cerillo
I. Cerillo
SPS. De Placido
S. De Placido
Approximately 5–10% of breast cancers are hereditary and their biology and prognosis appear to differ from those of sporadic breast cancers. In this study we compared the biological features and clinical characteristics of non metastatic breast cancer in patients with BRCA mutations versus patients with a family history suggesting hereditary breast cancer but without BRCA mutations (BRCA wild type) versus patients with sporadic disease, and correlated these findings with clinical outcome. We retrieved the clinical and biological data of 33 BRCA-positive, 66 BRCA-wild type and 1826 sporadic breast cancer patients contained in a single institution clinical database between 1980 and 2012. Specifically, we recorded age, tumor size, nodal status, treatment type, pattern of relapse, second primary incidence, outcome (disease-free survival and overall survival), and biological features (estrogen receptor [ER], progesterone receptor [PgR], tumor grade, proliferation and c-erbB2 status). Median follow-up was 70 months. BRCA-positive patients were significantly younger than sporadic breast cancer patients, and less likely to be ER-, PgR- or c-erbB2-positive than women with BRCA-wild type or sporadic breast cancer. Tumor size and grade, nodal status and proliferation did not differ among the three groups. Rates of radical mastectomy were 58, 42 and 37%, and those of conservative surgery were 42, 58 and 63% in women with BRCA-positive, BRCA-wild type and sporadic breast cancer (p = 0.03), respectively. The incidence of contralateral breast cancer was 12, 14 and 0% (p <0.0001) and the incidence of second primary tumors (non breast) was 9, 1 and 2% (p <0.0001) in BRCA-positive, BRCA-wild type and sporadic breast cancer, respectively. Median disease-free survival in years was 29 in BRCA-wild type, 19 in BRCA-positive and 14 in sporadic breast cancer patients (log-rank = 0.007). Median overall survival in years was not reached for BRCA-wild type, 19 for BRCA-positive and 13 for sporadic breast cancer patients (log-rank <0.0001). At multivariate analyses only BRCA-wild type status was related to a significant improvement in overall survival versus the sporadic breast cancer group (HR = 0,51; 95% CI (0,28–0,93) p = 0.028). The biology and outcome of breast cancer differ between patients with BRCA mutations, patients with a family history but no BRCA mutations and patients with sporadic breast cancer.

1 April 2001 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
MMMaurizio Montella
Maurizio Montella
ACAnna Crispo
Anna Crispo
GGerardo Botti
Gerardo Botti
MMMariarosaria de Marco
Mariarosaria de Marco
GBGiovanna de Bellis
Giovanna de Bellis
GDGiuseppe D'AIuto
Giuseppe D'AIuto

1 September 2002 in Preventive Medicine
Verified
Journal Article
Closed access
MMM. Montella
M. Montella
ACAnna Crispo
Anna Crispo
MGM. Grimaldi
M. Grimaldi
MMM.R. De Marco
M.R. De Marco
PAP.A. Ascierto
P.A. Ascierto
GFG. Fabbrocini
G. Fabbrocini